TY - JOUR
T1 - In vitro susceptibility to temafloxacin in female genital tract Bacteroides isolates
AU - Oshiro, Bryan T.
AU - Graham, Jack M.
AU - Blanco, Jorge D.
AU - Bishop, Karen D.
N1 - Funding Information:
This study was supported in part by a research grant from Abbott Laboratories.
PY - 1993/8
Y1 - 1993/8
N2 - Agar dilution susceptibility testing of temafloxacin, cefotetan, clindamycin, and ciprofloxacin was performed in 103 genital tract isolates of Bacteroides. The respective minimum inhibitory concentration inhibiting 90% of the strains tested were temafloxacin, 4 μg/ml; cefotetan, 256 μg/ml; clindamycin, 8 μg/ml; and ciprofloxacin, 16 μg/ml. Temafloxacin is effective against genital tract isolates of Bacteroides; therefore, clinical evaluation of temafloxacin in pelvic infections is warranted.
AB - Agar dilution susceptibility testing of temafloxacin, cefotetan, clindamycin, and ciprofloxacin was performed in 103 genital tract isolates of Bacteroides. The respective minimum inhibitory concentration inhibiting 90% of the strains tested were temafloxacin, 4 μg/ml; cefotetan, 256 μg/ml; clindamycin, 8 μg/ml; and ciprofloxacin, 16 μg/ml. Temafloxacin is effective against genital tract isolates of Bacteroides; therefore, clinical evaluation of temafloxacin in pelvic infections is warranted.
UR - http://www.scopus.com/inward/record.url?scp=0027275651&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027275651&partnerID=8YFLogxK
U2 - 10.1016/S0011-393X(05)80600-9
DO - 10.1016/S0011-393X(05)80600-9
M3 - Article
SN - 0011-393X
VL - 54
SP - 191
EP - 193
JO - Current Therapeutic Research - Clinical and Experimental
JF - Current Therapeutic Research - Clinical and Experimental
IS - 2
ER -